Enhance your nephrology practice with CME and tools focused on kidney medicine.
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Leonie Kraft, MD
Elevating CKD-aP Care: New Frontier
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
Improving Sleep and Mental Health in Patients with CKD-aP
CKD-aP or Something Else? Decoding the Diagnosis
CKD-aP Treatment Tool Kit
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Patrick Rossignol, MD, PhD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Sydney Tang, MBBS, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.